The long-term trend of the EPS is an important number as it indicates the present value of Yamana Gold Canada. The EPS growth rate, as it is typically called, is usually expressed as a percentage, which at this time is hard to estimate, but revenue growth has been -2.60% over the last twelve months. EPS growth is a vital measure of execution of the strategy for Yamana Gold Canada since it indicates how well the business is allocating resources to benefit shareholders.



Yamana Gold Canada is part of the metals and mining industry and basic materials sector. The company CEO is Peter Marrone. Yamana Gold Inc is a Canada-based gold miner operating a portfolio of mines in Brazil, Chile, Argentina, and Mexico. The company also holds stakes in the Alumbrera mine and Canadian Malartic mine.

Previous Intraday Performance:

The AUY shares had a previous change of 2.97% which opened at 2.73 and closed at 2.77. It moved to an intraday high of 2.79 and a low of 2.71.

SeekingAlpha:  Abitibi Royalties Doubles Down On Canadian Malartic Gold

Historical Performance:

Over the last five trading days, AUY shares returned 0.36% and in the past 30 trading days it returned 18.88%. Over three months, it changed 23.93%. In one year it has changed -19.32% and within that year its 52-week high was 3.53 and its 52-week low was 2.00. AUY stock is 38.50% above its 52 Week Low.

Our calculations result in a 200 day moving average of 2.64 and a 50 day moving average of 2.39. Right now, AUY stock is trading 5.05% above its 200 day moving average.

SeekingAlpha:  Abitibi Royalties Doubles Down On Canadian Malartic Gold

Liquidity:

The company has a market cap of $2.6b with 949.3m shares outstanding and a float of 949.3m shares. Trading volume was 14,018,277 shares and has experienced an average volume of 10,957,665 shares. Our calculation, using the current average volume and close price, leads me to believe that the liquidity is good.

Earnings:

The last annual reported EPS for Yamana Gold Canada was 0 which ended on 31st of December 2017. Based on 5 analyst estimates, the consensus EPS for the next quarter is 0.02. The trailing twelve month EPS is 0.15, which comes to a trailing twelve month PE of 18.47.

Below was the last reported quarterly earnings per share:
09-30-2018:  0.02
06-30-2018:  0.06
03-31-2018:  0.01
12-31-2017:  0.06



The dividend per share is currently 0.02, which is a dividend yield of 0.72%. Also, the payout ratio is 13.33%, therefore the dividend is safe according to our calculations.

Base on our calculations, the intrinsic value per share is 3.54, which means it might be undervalued and has a margin of safety of 21.70%

Indicators Also to Watch:

Based on the latest filings, there is 65.10% of institutional ownership. Short-interest was 12,318,396, which was 1.30% of shares outstanding. The short-interest ratio or days-to-cover ratio was 1.03. This stock has some short interest, but it might be normal and no need to worry if long the position.

I calculated the beta to be 0.86

Business Wire:  Aerpio Pharmaceuticals Announces Completion of Patient Dosing in TIME-2b Study of AKB-9778 in Diabetic Retinopathy

Fundamental Numbers:

Based on last reported financials, the company’s return on assets is -4.96%, profit margin is -17.65%, price-to-sales is 1.52 and price-to-book is 0.63.

Company Score Card:

Results are out of six:
 3  : Growth Expectations Result
 3  : Financial Safety Result
 0  : Past Performance Result
 2  : Valuation Result
 0  : Dividend Safety Result
 2  : Overall Result

Related Tags: , , ,

Jake McWilliams
I am an independent trader, analyst and algorithmic trading expert, having worked both for the sell side (brokerage) and the buy side (fund administration). I have been trading professionally for about 20 years. I trade stocks and forex and I play both long and short positions in underlying asset or through options. I have experience with discretionary and fully automated systems (Metatrader and Quantshare).

LEAVE A REPLY

Please enter your comment!
Please enter your name here